Jpmorgan Chase & CO Ironwood Pharmaceuticals Inc Transaction History
Jpmorgan Chase & CO
- $1.14 Trillion
- Q2 2024
A detailed history of Jpmorgan Chase & CO transactions in Ironwood Pharmaceuticals Inc stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,853,005 shares of IRWD stock, worth $7.76 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,853,005
Previous 1,185,225
56.34%
Holding current value
$7.76 Million
Previous $10.3 Million
17.03%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding IRWD
# of Institutions
246Shares Held
170MCall Options Held
11.2MPut Options Held
28.5K-
Black Rock Inc. New York, NY22.9MShares$95.9 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA21.6MShares$90.4 Million0.0% of portfolio
-
Sarissa Capital Management LP Greenwich, CT16.4MShares$68.7 Million18.04% of portfolio
-
State Street Corp Boston, MA9.24MShares$38.7 Million0.0% of portfolio
-
Pacer Advisors, Inc. Malvern, PA8.91MShares$37.3 Million0.15% of portfolio
About IRONWOOD PHARMACEUTICALS INC
- Ticker IRWD
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 153,231,008
- Market Cap $642M
- Description
- Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZE...